XML 23 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)
In Thousands, except Share data, unless otherwise specified
 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Operating expenses:    
Research and development expenses, net $ 4,047 $ 2,812
Marketing and business development expenses 351 298
General and administrative expenses 1,679 2,692
Total operating expenses 6,077 5,802
Operating loss (6,077) (5,802)
Financial income, net 1,332 1,512
Other income    240
Net loss (4,745) (4,050)
Unrealized gain (loss) on Investment in Evogene 569 (1,349)
Total comprehensive loss $ (4,176) $ (5,399)
Basic and diluted net loss per share $ (0.13) $ (0.12)
Weighted average number of Ordinary shares used in computing basic and diluted net loss per share 35,628,390 34,169,391